News articles about Oxford Immunotec Global PLC (NASDAQ:OXFD) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Oxford Immunotec Global PLC earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.7848840667334 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Shares of Oxford Immunotec Global PLC (OXFD) opened at $14.25 on Friday. Oxford Immunotec Global PLC has a 52-week low of $12.19 and a 52-week high of $19.51. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72.

Several research analysts have recently weighed in on the stock. Cowen Inc dropped their price target on shares of Oxford Immunotec Global PLC from $22.00 to $19.00 and set an “outperform” rating on the stock in a research note on Thursday, August 17th. Zacks Investment Research downgraded shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Piper Jaffray Companies restated a “buy” rating and set a $26.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. BTIG Research began coverage on shares of Oxford Immunotec Global PLC in a research report on Thursday, September 28th. They set a “buy” rating and a $21.00 price objective on the stock. Finally, ValuEngine downgraded shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $19.75.

ILLEGAL ACTIVITY WARNING: “Oxford Immunotec Global PLC (OXFD) Receiving Somewhat Positive Press Coverage, Report Finds” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/oxford-immunotec-global-plc-oxfd-receiving-somewhat-positive-press-coverage-report-finds/1723245.html.

In other news, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total transaction of $922,900.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global PLC stock in a transaction on Friday, September 1st. The shares were sold at an average price of $15.82, for a total transaction of $47,460.00. Following the completion of the sale, the director now owns 18,000 shares in the company, valued at $284,760. The disclosure for this sale can be found here. Insiders have sold a total of 61,000 shares of company stock worth $1,010,410 over the last 90 days. Insiders own 8.11% of the company’s stock.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Insider Buying and Selling by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.